DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20213079

Fetuin-A in association with metabolic syndrome and its components

Manisha Singh, Karli Sreenivasulu, Sarita Choudhary

Abstract


Background: Fetuin-A also known as α-2-Heremans-Schmid glycoprotein, is a multifunctional plasma glycoprotein. In developing countries like India, the metabolic syndrome (MetS) is on an exponential rise. The factors that characterize MetS are also associated with the atherosclerotic process, in which an important role is played by serum fetuin-A levels. The aim of present study is an assessment of serum fetuin-A level and its association with other components of MetS in age matched healthy controls and MetS subjects.

Methods: Total eighty (N=80) subjects (40 MetS cases and 40 age and gender matched controls) were included based on inclusion and exclusion criteria. The fasting venous samples were collected to measure the fasting glucose, lipid profile, glycated hemoglobin, insulin and fetuin-A levels. The serum fetuin levels were estimated by ELISA kit.

Results: The serum fetuin-A levels were significantly higher in MetS cases as compared to the control group (p value<0.001). Other components like insulin, HbA1c and HOMA-IR levels were raised in MetS compared to controls. In correlation analysis the serum fetuin-A levels were positively correlated with fasting insulin levels (r=0.36, p=0.02), fasting glucose (r=0.39, p=0.01) and triglycerides (r=0.34, p=0.03). Also, in receiver operating characteristic curve analysis the AUC for fetuin-A is 0.76 (95% CI: 0.65-0.86) was observed.

Conclusions: We found that serum fetuin-A levels were strongly and independently associated with MetS. Our finding suggests that fetuin-A could be a useful marker in clinical practice in the future for the early diagnosis of MetS.


Keywords


Fetuin-A, Metabolic syndrome, Insulin

Full Text:

PDF

References


Song A, Xu M, Bi Y, Xu Y, Huang Y, Li M, et al. Serum fetuin-A associates with type 2 diabetes and insulin resistance in Chinese adults. PLoS One. 2011;6(4):19228.

Ishibashi A. Serum Fetuin-A is an Independent Marker of Insulin Resistance in Japanese Men. J Atheroscler Thromb. 2010;17:925-33.

White MF. The insulin signalling system and the IRS proteins. Diabetologia. 1997;40:2-17.

Sotelo D, Rivada A, Garcia M, Castelao C, Baamonde I, Baltar J, et al. Visceral and subcutaneous adipose tissue express and secrete functional alpha2hsglycoprotein (fetuin a) especially in obesity. Endocrine. 2017;55(2):435-46.

Jialal I, Devaraj S, Bettaieb A, Haj F, Huet B. Increased adipose tissue secretion of Fetuin-A, lipopolysaccharide-binding protein and high-mobility group box protein 1 in metabolic syndrome. Atherosclerosis. 2015;241(1):130-7.

Mattinzoli D, Rastaldi MP, Ikehata M, Armelloni S, Pignatari C, Giardino LA, et al. FGF23-regulated production of Fetuin-A (AHSG) in osteocytes. Bone. 2016;83:35-47.

Penkova RS, Golemanov GM, Radionova ZV, Tonchev PT, Iliev SD, Penkov VV. Fetuin-A-Alpha2-Heremans-Schmid Glycoprotein: From Structure to a Novel Marker of Chronic Diseases Part 1. Fetuin-A as a Calcium Chaperone and Inflammatory Marker. J Biomed Clin Res. 2018;10:90-7.

Reinehr T, Roth CL. Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. J Clin Endocrinol Metab. 2008;93(11):4479-85.

Mann A, Makkar V, Mann S, Dhamija P, Soundarajan P. Fetuin‑A and vascular calcification in Indian end‑stage renal disease population. Indian J Nephrol. 2016;26:33-8.

Deepa P, Sasivathanam N. Serum Fetuin-A in Chronic Kidney Disease: A Promising Biomarker to Predict Cardiovascular Risk. Int J Sci Stud. 2016;4:138-43.

Pan X, Wen SW, Bestman PL, Kaminga AC, Acheampong K, Liu A. Fetuin-A in Metabolic syndrome: A systematic review and meta-analysis. PLoS One. 2020;15(3):229776.

Schochet D, Laughlin M, Ramakrishnan N, Jialal I. Exploratory metabolomics of metabolic syndrome: A status report. World J Diabetes. 2019;10(1):23-36.

Ruiz ME, Lans V, Torres I, Soto ME. Mechanisms Underlying Metabolic Syndrome-Related Sarcopenia and Possible Therapeutic Measures. Int J Mol Sci. 2019;20(3):647.

Trepanowski JF, Mey J, Varady KA. Fetuin-A: a novel link between obesity and related complications. Int J Obes. 2015;39(5):734-41.

Mathews ST, Rakhade S, Zhou X, Parker GC, Coscina DV, Grunberger G. Fetuin-null mice are protected against obesity and insulin resistance associated with aging. Biochem Biophys Res Commun. 2006;350(2):437-43.

Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Krober SM, et al. Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care. 2006;29(4):853-7.

Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest. 2016;126(1):12-22.

Srinivas PR, Wagner AS, Reddy LV, Deutsch DD, Leon MA, Goustin AS, et al. Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol Endocrinol. 1993;7(11):1445-55.

Mathews ST, Srinivas PR, Leon MA, Grunberger G. Bovine fetuin is an inhibitor of insulin receptor tyrosine kinase. Life Sci. 1997;61(16):1583-92.

Iroz A, Couty JP, Postic C. Hepatokines: unlocking the multi-organ network in metabolic diseases. Diabetologia. 2015;58(8):1699-703.

Ennequin G, Sirvent P, Whitham M. Role of exercise-induced hepatokines in metabolic disorders. Am J Physiol Endocrinol Metab. 2019;317(1):11-24.

Roshanzamir F, Miraghajani M, Rouhani MH, Mansourian M, Ghiasvand R, Safavi SM. The association between circulating fetuin-A levels and type 2 diabetes mellitus risk: systematic review and meta-analysis of observational studies. J Endocrinol Invest. 2018;41(1):33-47.